CareLit · DOI-Nachweis · Pneumologie
Once-daily tiotropium Respimat®: safety and tolerability results from five Phase III trials in adults with symptomatic asthma
DOI 10.1055/s-0036-1572093
Bibliografische Angaben
Nachweis in CareLit
Autor:innenE Beck, T Casale, NA Hanania, J Haughney, M Vandewalker, E Meltzer, P Paggiaro, M Engel, A Unseld, P Moroni-Zentgraf, H Kerstjens
ZeitschriftPneumologie
Ausgabe02/2016
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Introduction: Tiotropium Respimat® (tioR) has demonstrated efficacy as add-on to at least ICS in adult patients with symptomatic asthma. We present key safety data from five Phase III, double-blind, placebo-controlled, parallel-group trials of once-daily tioR add-on to at least ICS in adult patients with symptomatic asthma. Methods: Two 48-week trials (PrimoTinA-asthma®: NCT00776984/NCT00772538; n = 912) of tioR 5 µ…
Zitieren
Zitierempfehlung
E Beck, T Casale, NA Hanania, J Haughney, M Vandewalker, E Meltzer, P Paggiaro, M Engel, A Unseld, P Moroni-Zentgraf, H Kerstjens (2016) Once-daily tiotropium Respimat®: safety and tolerability results from five Phase III trials in adults with symptomatic asthma. Pneumologie (02). https://doi.org/10.1055/s-0036-1572093
Mit CareLit weiterarbeiten